Vol 3, No 5 (October 21, 2014): Translational Lung Cancer Research [The 14th Central European Lung Cancer Congress (CELCC)]

Preface

Preface
Robert Pirker, Caicun Zhou
PDF Pages: 269 Full Text (2617) Open Access Get Permission

Review Article

Lung cancer molecular epidemiology in China: recent trends
Caicun Zhou
PDF Pages: 270-279 Full Text (19516) Open Access Get Permission
Tobacco control in Poland—successes and challenges
Jacek Jassem, Krzysztof Przewoźniak, Witold Zatoński
PDF Pages: 280-285 Full Text (10817) Open Access Get Permission
Implementation of lung cancer screening: promises and hurdles
Helmut Prosch
PDF Pages: 286-290 Full Text (3514) Open Access Get Permission
Molecular testing in lung cancer in the era of precision medicine
Helmut H. Popper, Ales Ryska, József Tímár, Wlodzimierz Olszewski
PDF Pages: 291-300 Full Text (5665) Open Access Get Permission
Minimal requirements for the molecular testing of lung cancer
Helmut H. Popper, József Tímár, Ales Ryska, Wlodzimierz Olszewski
PDF Pages: 301-304 Full Text (4012) Open Access Get Permission
Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Robert Pirker
PDF Pages: 305-310 Full Text (18066) Open Access Get Permission
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
PDF Pages: 311-316 Full Text (8904) Open Access Get Permission

CELCC 2014 Abstracts

O1. EGFR, EML4-ALK and ROS 1 testing in Austrian patients with NSCLC: a multicentre study
Maximilian J. Hochmair, Sophia Holzer, Ulrike Setinek, Andrea Mohn-Staudne, Klaus Kirchbacher, Nina Dworan, Britt-Madeleine Arns, Andreas Fazekas, Kurt Patocka, Otto Chris Burghuber
ABSTRACT (3024) Open Access Get Permission
O2. Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
Juraj Kultan, Vitezslav Kolek, Ondrej Fiala, Jindrich Fínek, Miloš Pešek, Monika Šatánková, Jana Skrickova, Zbynek Bortlicek, Zuzana Zbožínková
ABSTRACT (2038) Open Access Get Permission
O3. Registry study in NSCLC patients with EGFR, ALK, or ROS1 mutations
Martin Filipits
ABSTRACT (2275) Open Access Get Permission
O4. Central data collection of management NSCLC stage III patients—study ongoing
Milada Zemanova, Karin Dieckmann, Zuzana Zbozinkova, Robert Pirker, Lubos Petruzelka
ABSTRACT (1917) Open Access Get Permission
O5. Prognostic significance of clinical T2aN0M0 GGO—dominant lung adenocarcinoma
Shota Nakamura, Tetsuo Taniguchi, Koji Kawaguchi, Takayuki Fukui, Futoshi Ishiguro, Koichi Fukumoto, Kohei Yokoi
ABSTRACT (2627) Open Access Get Permission
O6. Circulating tumor cells in the peripheral blood predict poor prognosis in surgically treated non-small cell lung cancer patients
Jiri Klein, Andrea Prokopova, Josef Srovnal, Josef Chudacek, Vitezslav Kolek, Ivona Grygarkova, Josef Dusa, Jozef Andel, Jozef Skarda, Marian Hajduch
ABSTRACT (1902) Open Access Get Permission
O7. Advantages and disadvantages of Cisplatin or carboplatin in adjuvant chemotherapy of NSCLC
Vitezslav Kolek
ABSTRACT (3257) Open Access Get Permission
O9. Results of multimodality therapy including radical resections for Pancoast tumors: a retrospective study in high-volume center
Ryuichi Waseda, Mir Alireza Hoda, Thomas Klikovits, Konrad Höetzenecker, Olivia Fösleitner, Karin Dieckmann, Sabine Zoechbauer, Robert Pirker, Helmut Prosch, Walter Klepetko
ABSTRACT (1852) Open Access Get Permission
O10. Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens
Michal Skronski, Adam Szpechcinski, Renata Langfort, Paulina Jagus, Agata Gizycka, Krystyna Maszkowska-Kopij, Tadeusz Orlowski, Kazimierz Roszkowski-Sliz, Joanna Chorostowska-Wynimko
ABSTRACT (2709) Open Access Get Permission
O11. The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location
Jana Skrickova, Zbynek Bortlicek, Karel Hejduk, Milos Pesek, Vitezslav Kolek, Leona Koubkova, Marcela Tomiskova, Jaromir Roubec, Libor Havel, Frantisek Salajka
ABSTRACT (2180) Open Access Get Permission
O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice
Nina Turnsek Hitij, Aleksander Sadikov, Lea Knez, Katja Mohorcic, Andraz Jakelj, Tanja Cufer
ABSTRACT (1875) Open Access Get Permission
O13. Subtype-specific KRAS mutations in advanced lung adenocarcinoma
Zoltan Lohinai, Mihaly Cserepes, Gyula Ostoros, Judit Moldvay, Bahil Ghanim, Viktoria Laszlo, Mir Alireza Hoda, Walter Klepetko, Balazs Hegedus, Balazs Dome
ABSTRACT (2122) Open Access Get Permission
P1. Molecular subclassification of NSCLC based on hsa-mir-205 and hsa-mir-21 expression using real time PCR
Radoslaw Charkiewicz, Miroslaw Kozlowski, Anetta Sulewska, Robert Milewski, Wieslawa Niklinska, Jacek Niklinski
ABSTRACT (1960) Open Access Get Permission
P2. VATS sentinel node biopsy reduces the need for systematic mediastinal lymphadenectomy in early stage NSCLC
Nenad Ilic, Josko Juricic, Vinko Markovic, Dragan Krnic, Nives Frleta Ilic, Darko Ilic
ABSTRACT (2564) Open Access Get Permission
P3. Therapeutic efficacy of single incision thoracoscopic surgery (SITS) for stage I lung cancer
Kyoji Hirai, Shingo Takeuchi, Yoshihito Iijima, Jitsuo Usuda
ABSTRACT (1782) Open Access Get Permission
P4. Aurora kinase MRNA level and gene copy number alterations in stage I-III. A non-small cell lung cancer
Oksana Kowalczuk, Miroslaw Kozlowski, Joanna Kisluk, Joanna Zurawska, Jacek Niklinski
ABSTRACT (2040) Open Access Get Permission
P5. Multidisciplinary thoracic tumor board conferences—review of the literature and institutional experience
Thomas Klikovits, Robert Pirker, Sabine Zöchbauer, Karin Dieckmann, Silvana Geleff, Helmut Prosch, Walter Klepetko, Mir Alireza Hoda
Full Text (2172) Open Access Get Permission
P6. Induction chemo- or chemoradiotherapy followed by resection for N2 positive NSCLC—a retrospective study
Olivia Foesleitner, Thomas Klikovits, Mir Alireza Hoda, Robert Pirker, Sabine Zoechbauer, Karin Dieckmann, Helmut Prosch, Madleine Arns, Peter Schenk, Walter Klepetko
ABSTRACT (1896) Open Access Get Permission
P7. Left carinal pneumonectomy with right bronchoplastic reconstruction via left thoracotomy
Jiri Klein, Josef Dusa, Jozef Andel
ABSTRACT (2035) Open Access Get Permission
P8. Efficacy of first-line pemetrexed/platinum chemotherapy in the treatment of advanced NSCLC in routine clinical practice
Katja Mohorcic, Nina Turnsek Hitij, Lea Knez, Aleksander Sadikov, Andraz Jakelj, Tanja Cufer
ABSTRACT (1688) Open Access Get Permission
P9. Response to gefitinib in advanced non-small cell lung cancer patients (NSCLC) with rare epidermal growth factor (EGFR) mutations—serbian experience 2011-2014
Davorin Radosavljevic, Dragana Jovanovic, Branislav Perin, Jelena Spasic, Bojan Zaric, Milena Cavic, Radmila Jankovic, Marta Velinovic
ABSTRACT (2478) Open Access Get Permission
P10. Influence of patient and tumor characteristics on the outcome of gefitinib therapy in advanced lung adenocarcinoma in two centers in Serbia
Jelena Spasic, Milena Cavic, Bojan Zaric, Branislav Perin, Sinisa Radulovic, Radmila Jankovic, Davorin Radosavljevic
ABSTRACT (2042) Open Access Get Permission
P11. Efficacy and safety of erlotinib in advanced squamous cell lung cancer
Marko Jakopovic, Branka Cucevic, Sanja Plestina, Suzana Kukulj, Mihovil Roglic, Silvana Smojver-Jezek, Mihovil Roglic, Marta Korsic, Gzim Redzepi, Miroslav Samarzija
ABSTRACT (2223) Open Access Get Permission
P12. Long term treatment with erlotinib in advanced non-small cell lung cancer patients
Mirjana Rajer, Matjaz Zwitter, Nadja Triller, Vilijem Kovac, Martina Vrankar
ABSTRACT (2058) Open Access Get Permission
P13. Epidemiologic, and therapeutic strategy of treated non-small cell lung cancer elderly patients in a single institution
Michail Vaslamatzis, Nektarios Alevizopoulos, Elisavet Patila, Charalambos Stathopoulos, Aikaterini Delaki, Charalambos Zoumblios, Theodoros Tegos, Theodora Kapou, Georgios Gkoumas, Vasiliki Ntalapera
ABSTRACT (1860) Open Access Get Permission
P14. Elderly patients with NSCLC with brain mets-need for combined targeted therapy
Manoj Behera, Faiz Ansari, G.K. Rath
ABSTRACT (1805) Open Access Get Permission
P15. Crizotinib in metastatic ALK-positive lung cancer—results from clinical practice in Slovakia
Peter Berzinec, Peter Kasan, Lukas Plank, Igor Andrasina, Robert Godal, Juraj Mazal, Andrea Cipkova, Lucia Denkova, Gabriela Chowaniecova, Iveta Kuliskova
ABSTRACT (2100) Open Access Get Permission
P16. Is type of EGFR mutation predictive for incidence and survival in lung adenocarcinoma patients with brain metastases?
Karmen Stanic, Nina Turnsek Hitij
ABSTRACT (2007) Open Access Get Permission
P17. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy
Ondrej Fiala, Milos Pesek, Jindrich Finek, Zbynek Bortlicek, Ondrej Topolcan
ABSTRACT (2410) Open Access Get Permission
P18. Predictive role of serum tumor markers NSE and TK in patients with advanced-stage NSCLC treated with EGFR-TKIs
Ondrej Fiala, Milos Pesek, Jindrich Finek, Lucie Benesova, Marek Minarik, Zbynek Bortlicek, Ondrej Topolcan
ABSTRACT (1867) Open Access Get Permission
P19. Overall survival in advanced lung cancer patients proposed to receive initial chemotherapy according to actual chemotherapy delivery
Lea Knez, Aleksander Sadikov, Andraž Jakelj, Katja Mohorcic, Nina Turnšek Hitij, Tanja Cufer
ABSTRACT (1948) Open Access Get Permission
P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs
Ondrej Fiala, Milos Pesek, Jindrich Finek, Lucie Benesova, Marek Minarik, Zbynek Bortlicek
ABSTRACT (2127) Open Access Get Permission
P21. Immunohistochemistry versus DNA testing for detection of EGFR mutations and ALK rearrangements in lung adenocarcinoma patients
Michal Skronski, Adam Szpechcinski, Renata Langfort, Paulina Jagus, Agata Gizycka, Dorota Giedronowicz, Joanna Chorostowska-Wynimko
ABSTRACT (2176) Open Access Get Permission
P22. The serum levels, phenotypes and expression of alpha-1-antitrypsin in non-small cell lung cancer—pilot study
Adam Szpechcinski, Renata Langfort, Beata Poplawska-Wisniewska, Dorota Giedronowicz, Wlodzimierz Kupis, Piotr Rudzinski, Jolanta Zaleska, Tadeusz Orlowski, Kazimierz Roszkowski-Sliz, Joanna Chorostowska-Wynimko
ABSTRACT (2572) Open Access Get Permission
P23. PET-CT confirms high rate of complete remissions among patients with advanced EGFR positive NSCLC treated with intercalated therapy
Matjaz Zwitter, Viljem Kovac, Karmen Stanic, Mirjana Rajer, Martina Vrankar
ABSTRACT (2267) Open Access Get Permission
P24. Epidemiologic, clinical characteristics of elderly non-small lung cancer patients treated in a single institution
Michail Vaslamatzis, Nektarios Alevizopoulos, Theodoros Tegos, Charalambos Zoublios, Theodora Kapou, Lambrini Kyriou, Charalambos Stathopoulos, Georgios Gkoumas, Elisavet Patila, Aikaterini Delaki
ABSTRACT (1709) Open Access Get Permission
P25. In vitro evaluation of the anticancer activity of ganetespib in combination with standard chemotherapeutics in small cell lung cancer (SCLC) cell lines
Gerhard Hamilton, Barbara Rath, Elisabeth Maritschnegg, Robert Zeillinger
ABSTRACT (1909) Open Access Get Permission
P26. Well differentiated neuroendocrine tumors of the lung—our experience
Jana Kulísková, Ondrej Fischer, Juraj Kultan, Vladan Polášek, Ivona Grygárková, Vitezslav Kolek, Tomáš Tichý
ABSTRACT (1737) Open Access Get Permission
P27. Small cell lung cancer and combined sparoganosis were suspected by multiple distant metastasis in PET-CT imaging of patient with colon cancer
Yoo Sang Yoon, Soon Hyo Park, Soo Young Jung, Youn Hee Choi, Dae Wook Yeh
ABSTRACT (2024) Open Access Get Permission
P28. Prediction of prognosis for small cell lung cancer based on genome-wide methylation analyses
Yuichi Saito, Genta Nagae, Noriko Motoi, Makoto Nishio, Sakae Okumura, Hiroyuki Aburatani, Yuichi Ishikawa
ABSTRACT (1950) Open Access Get Permission
P29. Oral topotecan in small cell lung cancer: treatment related side effects
Filip Popovic, Miroslav Samarzija, Suzana Kukulj, Gzim Redzepi, Mihovil Roglic, Davorka Mursic, Branka Cucevic, Sanja Plestina, Marko Jakopovic
ABSTRACT (2144) Open Access Get Permission
P30. Ki-67 expression in lung carcinoid tumors
Bernard Budimir, Suzana Kukulj, Luka Brcic, Luka Opasic, Branka Cucevic, Marina Serdarevic, Gordana Drpa, Slavica Sovic
ABSTRACT (2644) Open Access Get Permission
P31. Outcome after trimodality therapy with intracavitary hydrogen peroxide therapy in malignant pleural mesothelioma
Paul Stockhammer, Yawen Dong, Thomas Klikovits, Clemens Aigner, Shahrokh Taghavi, Gyoergy Lang, Sabine Zöchbauer, Karin Dieckmann, Walter Klepetko, Mir Alireza Hoda
ABSTRACT (2043) Open Access Get Permission
P32. Histological evaluation of mesotheliomas
Gregor Vlacic, Izidor Kern, Luka Brcic
ABSTRACT (1841) Open Access Get Permission
P33. Potential clinical relevance of in vitro migratory activity in malignant pleural mesothelioma
Tamás Garay, Eszter Molnár, Viktória László, Mir Alireza Hoda, József Tímár, Walter Klepetko, Walter Berger, Balázs Döme, Balázs Hegedus
ABSTRACT (1884) Open Access Get Permission
P34. Exploring cell plasticity in malignant pleural mesothelioma
Christina Wagner, Karin Schelch, Mir Alireza Hoda, Thomas Klikovits, Glen Reid, Walter Berger, Balazs Hegedus, Balazs Dome, Walter Klepetko, Michael Grusch
ABSTRACT (1996) Open Access Get Permission
P35. Fibroblast growth factor signals and their connection to micrornas in malignant pleural mesothelioma
Karin Schelch, Michaela Kirschner, Christina Wagner, Mir Alireza Hoda, Walter Klepetko, Balazs Dome, Balazs Hegedus, Walter Berger, Glen Reid, Michael Grusch
ABSTRACT (1809) Open Access Get Permission
P36. The prognostic potential of circulating and tissue activin A level in malignant pleural mesothelioma
Yawen Dong, Mir Alireza Hoda, Karin Schelch, Anita Rozsas, Viktoria Laszlo, Balazs Dome, Michael Grusch, Walter Berger, Walter Klepetko, Balazs Hegedus
ABSTRACT (2002) Open Access Get Permission
P37. Surgical strategy for stage III thymoma by video assisted thoracoscopic surgery (VAT-T) with lateral thoracotomy
Shingo Takeuchi, Kyoji Hirai, Yoshihito Iijima, Jitsuo Usuda
ABSTRACT (1895) Open Access Get Permission
P38. Extraesophageal reflux disease and lung cancer
Milos Pesek, Turkova-Sedlackova Terezie, Bittenglova Radka, Fremundova Lucie
ABSTRACT (1904) Open Access Get Permission
P39. Management of respiratory symptoms in patients with advanced lung cancer
Jana Skrickova, Zdenek Merta
ABSTRACT (1886) Open Access Get Permission
P40. Applying digital tomosynthesis (DTS) to diagnose lung cancer and follow up patients
Klara Szondy, Akos Horvath, Zoltan Sutto, Adrian Kis, Gabor Horvath, Gyorgy Losonczy
ABSTRACT (1866) Open Access Get Permission
P41. Scedosporium apiospermum mycetoma in a lung cancer patient—case report
Nektarios Alevizopoulos, Apostolos Laskarakis, Theodoros Vagdatlis, Vasiliki Ntalapera, Anna Skoula, Theodoros Tegos, Theodoros Argirakos, Charis Margariti, Michail Vaslamatzis
ABSTRACT (1912) Open Access Get Permission
P42. Multiple neoplasms consist of lung cancer and hematological malignancies
Kazuhiko Natori, Susumu Ishihara, Daisuke Nagase, Akiko Sakai, Motohiro Kato, Yasunobu Kuraishi, Kazuho Arai, Haruka Izumi
ABSTRACT (1735) Open Access Get Permission
P43. Therapy-related leukemia after lung cancer therapy
Kazuhiko Natori, Daisuke Nagas, Susumu Ishihara, Akiko Sakai, Motohiro Kato, Yasunobu Kuraishi, Kazuho Arai, Haruka Izumi
ABSTRACT (1895) Open Access Get Permission
P44. Activin A is novel circulating biomarker in lung cancer
Anita Rozsas, Mir Alireza Hoda, Thomas Klikovits, Karin Schlech, Viktoria Laszlo, Michael Grusch, Walter Berger, Walter Klepetko, Balazs Hegedus, Balazs Dome
ABSTRACT (2165) Open Access Get Permission
P45. New method of brachytherapy catheter stabilization in proximal trachea
Jiri Votruba, Petra Zemanova, Jiri Benes
ABSTRACT (1889) Open Access Get Permission
P46. Use of 18-FDG PET/CT in the radiotherapy planning of lung cancer—our updated experiences
Andrea Masarykova, Danijela Scepanovic, Pavol Povinec, Pavol Bires, Margita Pobijakova
ABSTRACT (1876) Open Access Get Permission

Disclosure:

The focused issue “The 14th Central European Lung Cancer Congress (CELCC)” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Robert Pirker and Caicun Zhou served as the unpaid Guest Editors for the focused issue.